Developer docs
API playgroundTry for free, no card

Search company profiles

Nuvaira

Full company profile

uuid0000omm

Namestring
Nuvaira
Legal namestring
Nuvaira, Inc.
Websiteurl
nuvaira.com
Company typeenum
Private
Founded yearint
2008
Descriptiontext

Nuvaira is a clinical-stage medical device company headquartered in Minneapolis, Minnesota, founded in 2008 to develop catheter-based therapies for overactive airway nerves in chronic obstructive pulmonary disease (COPD). Its core product, the dNerva Lung Denervation System, performs Targeted Lung Denervation (TLD) — a one-time, 60–90 minute outpatient bronchoscopic procedure under general anesthesia in which a balloon-mounted radiofrequency catheter delivers circumferential ablation to pulmonary nerve branches in the main bronchi, permanently disrupting parasympathetic acetylcholine release to produce a durable "always on" bronchodilator effect. The system comprises the disposable dNerva RF catheter (available in three sizes for 9–16.5 mm bronchi), the Nuvaira Console (RF generator with thermoelectric cooling and graphical interface), and the optional EsoCool esophageal cooling catheter; its DualCool technology simultaneously cools the airway wall and esophagus during RF delivery to protect surrounding tissue. The company serves pulmonologists, interventional bronchoscopists, and moderate-to-severe COPD patients who remain symptomatic on dual or triple inhaled therapy, with clinical development conducted across 40 sites in the US (25) and Europe (15) under the AIRFLOW-3 pivotal trial (N=464).

Nuvaira holds FDA Breakthrough Device Designation (2020-2021) and CE Mark approval for EU commercialization, with more than 70 patents issued and pending worldwide and 18 peer-reviewed publications supporting safety and a 62% reduction in severe exacerbation risk at two years. The company is pre-revenue in the US (device under IDE investigation, not commercially available), with planned commercialization through direct hospital sales of capital equipment consoles plus recurring disposable catheter revenue. The business has been funded through venture capital rounds totaling approximately $178 million in disclosed financing ($49M in 2014-2015, $79M in 2019, $50M in 2022) plus active exempt securities offerings through 2026, with no commercial product revenue disclosed.

Short descriptiontext

Nuvaira is a clinical-stage medical device company developing the dNerva Lung Denervation System, a catheter-based radiofrequency platform that performs one-time outpatient bronchoscopic procedures to disrupt pulmonary nerves and treat moderate-to-severe COPD patients who remain symptomatic on inhaled therapy.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMaple Grove, United States
HQ citystring
Maple Grove
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
targeted lung denervation, COPD treatment devices, bronchoscopic ablation, radiofrequency catheter systems, interventional pulmonology
Industry2 codes
PRIMARYHLAKANAE
COPD & Chronic Bronchitis Management
SECONDARYHLAKANAJ
Bronchoscopy & Interventional Pulmonology
NAICS code1 code
  • Surgical Appliance and Supplies Manufacturing339113
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Interventional Pulmonology Medical Devices
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Medical Device Sales (Post-Regulatory Approval)
TypeHardware Sales
Description

Nuvaira is a clinical-stage medical device company. The dNerva Lung Denervation System has CE Mark regulatory approval (EU) and is under FDA pivotal investigation in the US. Revenue will be generated from direct hospital sales of the dNerva system (catheters, console) upon regulatory approvals. The system includes a console (capital equipment) and disposable catheters, creating a recurring revenue opportunity through procedural consumables.

nuvaira.com
2Financing/Exempt Securities Offerings
TypeSubscription Recurring
Description

Nuvaira has raised capital through multiple exempt securities offerings under SEC Rule 506(b). The company has sold approximately $35.76 million of a $63.58 million offering as of February 2026, with prior offerings of $17.25 million (2023) and $68.23 million (2022). These are not revenue from operations but capital raises to fund R&D and clinical trials.

sec.gov
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
Pricing details1 tier
1dNerva Lung Denervation System - Not commercially available in USA
ModelOtherBilling cadenceMulti-year contract
Notes

The device is under clinical investigation (IDE study) and not yet commercially available in the United States. The system has received CE Mark regulatory approval in Europe, where commercialization may occur. Pricing for hospital capital equipment and disposable medical devices is typically not publicly disclosed and is negotiated through group purchasing organizations (GPOs) and hospital contracting processes.

nuvaira.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1dNerva Lung Denervation System
Description

A catheter-based system used to complete a one-time, out-patient, bronchoscopic procedure to disrupt nerve input to and from the lungs to reduce the clinical consequences of neural hyperactivity.

nuvaira.com
+2 more records
Core offering1 text field

Nuvaira develops and commercializes the dNerva Lung Denervation System, a catheter-based medical device platform that performs Targeted Lung Denervation (TLD) for the treatment of moderate-to-severe COPD. The system consists of a disposable dNerva RF ablation catheter, the Nuvaira Console (capital equipment), and the EsoCool esophageal cooling catheter, which together deliver a one-time 60-90 minute outpatient bronchoscopic procedure that permanently disrupts pulmonary nerve input to create a durable bronchodilator effect.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 62% reduction in risk of severe COPD exacerbations at 2 years (AIRFLOW-2 trial)
+5 more records
Product overview1 text field

Nuvaira offers the dNerva Lung Denervation System, a novel catheter-based medical device platform for treating COPD through Targeted Lung Denervation (TLD). The system consists of the dNerva RF ablation catheter (disposable, available in multiple sizes for different bronchi diameters), the Nuvaira Console (which houses the RF generator, thermoelectric cooling plate, and pump), and the EsoCool esophageal cooling catheter for tissue protection. The DualCool technology feature enables simultaneous RF energy delivery and cooling. This is a single primary product with multiple component and feature variations—a complete therapeutic system for a one-time outpatient bronchoscopic procedure.

Product and service3 records
1dNerva Lung Denervation System
CategoryInterventional Pulmonology Medical Device System
Description

Catheter-based medical device system that performs Targeted Lung Denervation (TLD), a one-time 60-90 minute outpatient bronchoscopic procedure under general anesthesia that permanently disrupts pulmonary nerve input to the lungs to reduce the clinical consequences of neural hyperactivity in moderate-to-severe COPD patients. The system comprises the dNerva RF catheter, the Nuvaira Console, and the optional EsoCool esophageal cooling catheter.

2Nuvaira Console
CategoryMedical Device Capital Equipment
Description

Capital equipment console including a thermoelectric plate and pump that cools fluid circulating through the dNerva catheter to protect the airway wall during RF energy delivery. Features a graphical user interface with a prompt screen to control the console and guide the user through the Targeted Lung Denervation procedure.

3EsoCool Esophageal Cooling Catheter
CategoryInterventional Pulmonology Accessory Device
Description

Esophageal cooling catheter designed for protection during lung denervation that actively cools the esophagus throughout RF ablation, providing additional tissue protection during the Targeted Lung Denervation procedure.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Pulmonx markets the Zephyr Endobronchial Valve, a bronchoscopic device for lung volume reduction in emphysema/COPD patients. It is the closest direct procedural peer to Nuvaira in interventional pulmonology targeting severe COPD, sharing the same specialist customer base, bronchoscopic delivery model, and need for specialty reimbursement.

TypeDirect peer
Description

Spiration, a subsidiary of Olympus, produces the Spiration Valve System for bronchoscopic lung volume reduction in emphysema patients. It competes directly in the interventional COPD procedural space with Nuvaira's dNerva, sharing the bronchoscopic, specialist-delivered model and severe-COPD patient population.

TypeDirect peer
Description

PneumRx, acquired by BTG (now Boston Scientific), developed the RePneu Coil for bronchoscopic lung volume reduction in emphysema. It is a direct procedural peer to Nuvaira in interventional COPD therapy and shares the bronchoscopic, hospital-based, specialist-physician delivery model.

TypeBroad incumbent
Description

Olympus is the dominant manufacturer of flexible bronchoscopes and a broad portfolio of interventional pulmonology devices. As the platform on which Nuvaira's dNerva catheter is delivered, Olympus is both a critical enabling partner and a broad incumbent whose portfolio could expand to compete with or absorb TLD-like technologies.

TypeBroad incumbent
Description

Boston Scientific owns PneumRx and operates a large interventional pulmonology and chronic respiratory device portfolio. It is a broad incumbent that competes in procedural COPD therapy and is a likely strategic acquirer of Nuvaira if TLD reaches commercial approval.

TypeBroad incumbent
Description

Medtronic offers bronchoscopy-enabled diagnostics and therapies (including acquired superDimension navigation) and competes in interventional pulmonology broadly. It is a broad incumbent whose portfolio overlaps with the procedural COPD space and could view Nuvaira as complementary.

TypeEmerging player
Description

Body Vision Medical develops AI-driven bronchoscopic lung navigation and biopsy tools for pulmonary nodules. While focused on diagnostics rather than COPD treatment, it is an emerging player sharing the bronchoscopic, pulmonologist-targeted commercial channel that Nuvaira depends on.

TypeEmerging player
Description

Broncus Medical develops interventional pulmonology tools including lung navigation and biopsy systems for COPD and lung cancer. It is an emerging player operating in the same bronchoscopic, pulmonologist channel and addressing overlapping patient populations.

TypeEmerging player
Description

Inspire Medical Systems developed an implanted neurostimulation device for obstructive sleep apnea, sharing with Nuvaira a procedural, neuromodulation-based approach to airway disease. Inspire's CEO also chairs Nuvaira's board, signaling strategic and operational adjacency between the two device platforms.

TypeOthers
Description

AstraZeneca is a leading COPD pharmaceutical manufacturer (Symbicort, Breztri, Fasenra) whose triple-therapy and biologic inhaler portfolios compete for the same moderate-to-severe COPD patient population. It is thematically adjacent as the dominant incumbent pharmacotherapy whose continued innovation could narrow TLD's addressable pool.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds13 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors12 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Nuvaira

Interventional Pulmonology Medical Devicesnuvaira.com

Nuvaira is a clinical-stage medical device company developing the dNerva Lung Denervation System, a catheter-based radiofrequency platform that performs one-time outpatient bronchoscopic procedures to disrupt pulmonary nerves and treat moderate-to-severe COPD patients who remain symptomatic on inhaled therapy.

What Nuvaira does

Nuvaira is a clinical-stage medical device company headquartered in Minneapolis, Minnesota, founded in 2008 to develop catheter-based therapies for overactive airway nerves in chronic obstructive pulmonary disease (COPD). Its core product, the dNerva Lung Denervation System, performs Targeted Lung Denervation (TLD) — a one-time, 60–90 minute outpatient bronchoscopic procedure under general anesthesia in which a balloon-mounted radiofrequency catheter delivers circumferential ablation to pulmonary nerve branches in the main bronchi, permanently disrupting parasympathetic acetylcholine release to produce a durable "always on" bronchodilator effect. The system comprises the disposable dNerva RF catheter (available in three sizes for 9–16.5 mm bronchi), the Nuvaira Console (RF generator with thermoelectric cooling and graphical interface), and the optional EsoCool esophageal cooling catheter; its DualCool technology simultaneously cools the airway wall and esophagus during RF delivery to protect surrounding tissue. The company serves pulmonologists, interventional bronchoscopists, and moderate-to-severe COPD patients who remain symptomatic on dual or triple inhaled therapy, with clinical development conducted across 40 sites in the US (25) and Europe (15) under the AIRFLOW-3 pivotal trial (N=464).

Nuvaira holds FDA Breakthrough Device Designation (2020-2021) and CE Mark approval for EU commercialization, with more than 70 patents issued and pending worldwide and 18 peer-reviewed publications supporting safety and a 62% reduction in severe exacerbation risk at two years. The company is pre-revenue in the US (device under IDE investigation, not commercially available), with planned commercialization through direct hospital sales of capital equipment consoles plus recurring disposable catheter revenue. The business has been funded through venture capital rounds totaling approximately $178 million in disclosed financing ($49M in 2014-2015, $79M in 2019, $50M in 2022) plus active exempt securities offerings through 2026, with no commercial product revenue disclosed.

Nuvaira firmographics

Firmographics
Name
Nuvaira
Legal name
Nuvaira, Inc.
Website
https://nuvaira.com
Company type
Private
Founded year
2008
Operating status
Operating
Headcount range
11–50 employees
Short description
Nuvaira is a clinical-stage medical device company developing the dNerva Lung Denervation System, a catheter-based radiofrequency platform that performs one-time outpatient bronchoscopic procedures to disrupt pulmonary nerves and treat moderate-to-severe COPD patients who remain symptomatic on inhaled therapy.
Ownership category
akta.pro rank

Nuvaira industry classification

Industry
Product category
Interventional Pulmonology Medical Devices
NAICS
Surgical Appliance and Supplies Manufacturing (339113)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAKANAE
COPD & Chronic Bronchitis Management
SECONDARYHLAKANAJ
Bronchoscopy & Interventional Pulmonology

Keywords

  • Targeted lung denervation
  • COPD treatment devices
  • Bronchoscopic ablation
  • Radiofrequency catheter systems
  • Interventional pulmonology

Where Nuvaira is headquartered

Location

Headquarters

HQ city
Maple Grove
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Nuvaira business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Medical Device Sales (Post-Regulatory Approval): Nuvaira is a clinical-stage medical device company. The dNerva Lung Denervation System has CE Mark regulatory approval (EU) and is under FDA pivotal investigation in the US. Revenue will be generated from direct hospital sales of the dNerva system (catheters, console) upon regulatory approvals. The system includes a console (capital equipment) and disposable catheters, creating a recurring revenue opportunity through procedural consumables.
  2. Financing/Exempt Securities Offerings: Nuvaira has raised capital through multiple exempt securities offerings under SEC Rule 506(b). The company has sold approximately $35.76 million of a $63.58 million offering as of February 2026, with prior offerings of $17.25 million (2023) and $68.23 million (2022). These are not revenue from operations but capital raises to fund R&D and clinical trials.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractdNerva Lung Denervation System - Not commercially available in USA

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Nuvaira product offering

Product offering

Core offering

Nuvaira develops and commercializes the dNerva Lung Denervation System, a catheter-based medical device platform that performs Targeted Lung Denervation (TLD) for the treatment of moderate-to-severe COPD. The system consists of a disposable dNerva RF ablation catheter, the Nuvaira Console (capital equipment), and the EsoCool esophageal cooling catheter, which together deliver a one-time 60-90 minute outpatient bronchoscopic procedure that permanently disrupts pulmonary nerve input to create a durable bronchodilator effect.

Product overview

Nuvaira offers the dNerva Lung Denervation System, a novel catheter-based medical device platform for treating COPD through Targeted Lung Denervation (TLD). The system consists of the dNerva RF ablation catheter (disposable, available in multiple sizes for different bronchi diameters), the Nuvaira Console (which houses the RF generator, thermoelectric cooling plate, and pump), and the EsoCool esophageal cooling catheter for tissue protection. The DualCool technology feature enables simultaneous RF energy delivery and cooling. This is a single primary product with multiple component and feature variations—a complete therapeutic system for a one-time outpatient bronchoscopic procedure.

Differentiator

Problem solved

Functional benefit

Brands

  • dNerva Lung Denervation System: A catheter-based system used to complete a one-time, out-patient, bronchoscopic procedure to disrupt nerve input to and from the lungs to reduce the clinical consequences of neural hyperactivity.
  • DualCool
  • EsoCool

Products and services

  • dNerva Lung Denervation System Catheter-based medical device system that performs Targeted Lung Denervation (TLD), a one-time 60-90 minute outpatient bronchoscopic procedure under general anesthesia that permanently disrupts pulmonary nerve input to the lungs to reduce the clinical consequences of neural hyperactivity in moderate-to-severe COPD patients. The system comprises the dNerva RF catheter, the Nuvaira Console, and the optional EsoCool esophageal cooling catheter.
  • Nuvaira Console Capital equipment console including a thermoelectric plate and pump that cools fluid circulating through the dNerva catheter to protect the airway wall during RF energy delivery. Features a graphical user interface with a prompt screen to control the console and guide the user through the Targeted Lung Denervation procedure.
  • EsoCool Esophageal Cooling Catheter Esophageal cooling catheter designed for protection during lung denervation that actively cools the esophagus throughout RF ablation, providing additional tissue protection during the Targeted Lung Denervation procedure.

Quantifiable outcome

  • 62% reduction in risk of severe COPD exacerbations at 2 years (AIRFLOW-2 trial)
  • +5 more outcomes

Companies that use Nuvaira

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles1 record

Nuvaira technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Nuvaira partnerships and signals

Strategic signal

Scale indicators10 records

Recent moves6 records

Expansion highlights5 records

Nuvaira competitors and assessment

Company assessment

Direct peers

  • Pulmonx: Pulmonx markets the Zephyr Endobronchial Valve, a bronchoscopic device for lung volume reduction in emphysema/COPD patients. It is the closest direct procedural peer to Nuvaira in interventional pulmonology targeting severe COPD, sharing the same specialist customer base, bronchoscopic delivery model, and need for specialty reimbursement.
  • Spiration (Olympus): Spiration, a subsidiary of Olympus, produces the Spiration Valve System for bronchoscopic lung volume reduction in emphysema patients. It competes directly in the interventional COPD procedural space with Nuvaira's dNerva, sharing the bronchoscopic, specialist-delivered model and severe-COPD patient population.
  • PneumRx (Boston Scientific): PneumRx, acquired by BTG (now Boston Scientific), developed the RePneu Coil for bronchoscopic lung volume reduction in emphysema. It is a direct procedural peer to Nuvaira in interventional COPD therapy and shares the bronchoscopic, hospital-based, specialist-physician delivery model.

Broad incumbents

  • Olympus: Olympus is the dominant manufacturer of flexible bronchoscopes and a broad portfolio of interventional pulmonology devices. As the platform on which Nuvaira's dNerva catheter is delivered, Olympus is both a critical enabling partner and a broad incumbent whose portfolio could expand to compete with or absorb TLD-like technologies.
  • Boston Scientific: Boston Scientific owns PneumRx and operates a large interventional pulmonology and chronic respiratory device portfolio. It is a broad incumbent that competes in procedural COPD therapy and is a likely strategic acquirer of Nuvaira if TLD reaches commercial approval.
  • Medtronic: Medtronic offers bronchoscopy-enabled diagnostics and therapies (including acquired superDimension navigation) and competes in interventional pulmonology broadly. It is a broad incumbent whose portfolio overlaps with the procedural COPD space and could view Nuvaira as complementary.

Emerging players

  • Body Vision Medical: Body Vision Medical develops AI-driven bronchoscopic lung navigation and biopsy tools for pulmonary nodules. While focused on diagnostics rather than COPD treatment, it is an emerging player sharing the bronchoscopic, pulmonologist-targeted commercial channel that Nuvaira depends on.
  • Broncus Medical: Broncus Medical develops interventional pulmonology tools including lung navigation and biopsy systems for COPD and lung cancer. It is an emerging player operating in the same bronchoscopic, pulmonologist channel and addressing overlapping patient populations.
  • Inspire Medical Systems: Inspire Medical Systems developed an implanted neurostimulation device for obstructive sleep apnea, sharing with Nuvaira a procedural, neuromodulation-based approach to airway disease. Inspire's CEO also chairs Nuvaira's board, signaling strategic and operational adjacency between the two device platforms.

Others

  • AstraZeneca: AstraZeneca is a leading COPD pharmaceutical manufacturer (Symbicort, Breztri, Fasenra) whose triple-therapy and biologic inhaler portfolios compete for the same moderate-to-severe COPD patient population. It is thematically adjacent as the dominant incumbent pharmacotherapy whose continued innovation could narrow TLD's addressable pool.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Nuvaira social profiles

Digital presence

Nuvaira compliance and trust

Trust signal

Compliance2 records

Nuvaira financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Nuvaira leadership team

Management profile

Number of profiles

Profiles11 records

Nuvaira funding detail

Funding detail

Funding overview

Funding rounds13 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Nuvaira M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nuvaira

What does Nuvaira do?

Nuvaira develops and commercializes the dNerva Lung Denervation System, a catheter-based medical device platform that performs Targeted Lung Denervation (TLD) for the treatment of moderate-to-severe COPD. The system consists of a disposable dNerva RF ablation catheter, the Nuvaira Console (capital equipment), and the EsoCool esophageal cooling catheter, which together deliver a one-time 60-90 minute outpatient bronchoscopic procedure that permanently disrupts pulmonary nerve input to create a durable bronchodilator effect.

Is Nuvaira a public or private company?

Nuvaira is a private company. It is classified as venture growth investor backed and is currently operating.

When was Nuvaira founded?

Nuvaira was founded in 2008. It employs 11 to 50 people.

Where is Nuvaira based?

Nuvaira is headquartered in Maple Grove, United States, in the North America region.

How does Nuvaira make money?

Two revenue lines are on record. Medical Device Sales (Post-Regulatory Approval) is the primary driver. The others are financing/Exempt Securities Offerings.

Who are Nuvaira's main competitors?

Direct peers on record are Pulmonx, Spiration (Olympus) and PneumRx (Boston Scientific). Broad incumbents are Olympus, Boston Scientific and Medtronic. Emerging players are Body Vision Medical, Broncus Medical and Inspire Medical Systems. AstraZeneca is listed as an others.

Does Nuvaira have an API?

No public API is recorded for Nuvaira.

What industry is Nuvaira in?

Nuvaira's product category is Interventional Pulmonology Medical Devices. Its primary akta.pro industry code is HLAKANAE, COPD & Chronic Bronchitis Management, with a secondary code of HLAKANAJ, Bronchoscopy & Interventional Pulmonology. Its NAICS code is 339113 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Respiratory TherapyLung Denervation Trial to Target COPD PhenotypeNuvaira announced the enrollment of the first patient in its pivotal AIRFLOW-4 trial for dNerva, a one-time lung denervation therapy targeting COPD patients with small airways disease. The treatment aims to provide constant bronchodilation without daily inhaler adherence, based on previous data showing improved lung function and quality of life. Concurrently, Nuvaira appointed Lisa Flaherty as chief strategy officer following the closure of funding for the trial.MorningstarLung Denervation Trial targets Novel COPD PhenotypeNuvaira announced the treatment of the first patient in its pivotal AIRFLOW-4 trial for dNerva® targeted lung denervation therapy, a one-time outpatient procedure for COPD. The company simultaneously appointed Lisa Flaherty as Chief Strategy Officer to support the completion of the trial following recent funding closure. Previous data from the AIRFLOW-3 trial indicated that patients with small airways disease experienced meaningful improvements in lung function and quality of life.PR NewswireLung Denervation Trial targets Novel COPD PhenotypeNuvaira announced the first patient treated in its AIRFLOW-4 trial of dNerva lung denervation for COPD. Post-hoc analysis at one year showed meaningful improvements in lung function, exacerbation rates, and quality of life versus sham. The company closed funding to complete the trial and appointed a new chief strategy officer.American City Business JournalsTable of Experts: Smart technologies in manufacturingA Minneapolis-St. Paul Business Journal panel discussed smart manufacturing technologies, featuring panelists from Uponor, Nuvaira, and Starkey. They highlighted AI-driven quality monitoring, MES reducing downtime by 80%, and digital integration with suppliers. Future plans include broader AI deployment and real-time data sharing across the supply chain.SecSEC FORM DThe Securities and Exchange Commission received a Form D filing from NuVaira, Inc. indicating an offering of securities amounting to $17,251,125. The filing details the company’s structure and intends to last for less than a year, with a total of 39 investors already involved in the offering.PR Newswire200ème étape de traitement pour l'essai AIRFLOW-3 sur la BPCONuvaira announced two key milestones in its AIRFLOW-3 pivotal trial for COPD: the 200th patient treated in the trial and the 300th patient worldwide treated with the dNerva® Targeted Lung Denervation (TLD) therapy across five clinical studies. Dr. Gerard Criner at Temple University and Dr. Pallav Shah at Imperial College London conducted major patient enrollments in the trial. The company also secured an additional $50 million financing commitment from Innovatus Capital Partners to complete the AIRFLOW-3 trial and obtain FDA approval.PR Newswire200th Treatment Milestone for AIRFLOW-3 COPD TrialNuvaira announced two clinical treatment milestones for its dNerva® Targeted Lung Denervation therapy, with 200 patients now treated in the AIRFLOW-3 pivotal trial—the first interventional COPD trial targeting exacerbation reduction as a primary endpoint—and 300 patients treated worldwide across five clinical trials. The company recently secured $50 million in debt and equity financing from Innovatus Capital Partners to complete the trial and pursue U.S. FDA approval. COPD exacerbations account for approximately two-thirds of the $49 billion annual cost of COPD care in the U.S., underscoring the potential healthcare burden reduction if the therapy succeeds.PR NewswireHito de 200 tratamientos en el ensayo AIRFLOW-3 sobre la EPOCNuvaira announced that its pivotal AIRFLOW-3 clinical trial for COPD has treated 200 patients, while a total of 300 patients worldwide have received the dNerva Targeted Lung Denervation therapy across five trials. The company also secured an additional $50 million in debt and equity financing from Innovatus Capital Partners to complete the trial and seek FDA approval.SecSEC FORM DNuVaira, Inc. filed a Form D with the Securities and Exchange Commission to report an exempt offering of equity securities under Rule 506(b). The filing discloses a total offering amount of $68,228,304 USD, with $31,337,640 USD already sold to 49 investors as of July 13, 2020.